Advances in understanding behavioral phenotypes in neurogenetic syndromes

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 154, Issue 4, 2010, Pages 389-399

  Harris, James C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior phenotype; Developmental trajectory; Fragile X; Lesch Nyhan; Neurogenetic; Neuroimaging; Psychopathology; Williams Beuren

Indexed keywords

2 METHYL 6 [PHENYLETHYNYL] PYRIDINE; ANXIOLYTIC AGENT; FENOBAM; FRAGILE X PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; ARTICLE; AUTOMUTILATION; BEHAVIOR; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITION; COMPULSION; DEVELOPMENTAL GENETICS; DRUG SAFETY; FMR1 GENE; GENE; GENETIC DISORDER; GENETIC LINKAGE; HUMAN; HYPERPHAGIA; INTELLECTUAL DISABILITY; LESCH NYHAN SYNDROME; MENTAL DEFICIENCY; METHODOLOGY; MOOD DISORDER; MOUSE; NEUROGENETIC SYNDROME; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PHENOTYPE; PRADER WILLI SYNDROME; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR; GENETIC DISEASES, INBORN; GENETICS, MEDICAL; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMAN DEVELOPMENT; HUMANS; MODELS, ANIMAL; NERVOUS SYSTEM DISEASES; PHENOTYPE; PSYCHOPATHOLOGY;

EID: 78049367819     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30276     Document Type: Article

References (75)

1. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377.
2. Bellugi U, Lichtenberger L, Galaburda A, Korenberg JR. 1999. Bridging cognition, the brain and molecular genetics: Evidence from Williams syndrome. Trends Neurosci 22:197-207.
3. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R. 2009. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46:266-271.
4. Breese GR, Baumeister AA, McCown TJ. 1984. Behavioral differences between neonatal and adult-6-hydorxydopamine treated rats to dopamine gonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231:343-354.
5. Breese GR, Criswell E, Duncan GE. 1990. A dopamine deficiency model of Lesch-Nyhan disease-The neonatal-6-OHDA-lesioned rat. Brain Res Bull 25:477-484.
6. Buck v. Bell. 1927. 274 U.S. 200.
7. Critchley M, Earl CJC. 1932. Tuberous sclerosis and allied conditions. Brain 55:311-346.
8. Dai L, Bellugi U, Chen XN, Pulst-Korenberg AM, Järvinen-Pasley A, Tirosh-Wagner T, Eis PS, Graham J, Mills D, Searcy Y, Korenberg JR. 2009. Is it Williams syndrome? GTF2IRD1 implicated in visual-spatial construction and GTF2I in sociability revealed by high resolution arrays. Am J Med Genet Part A 149A:302-314.
9. de Vries PJ. 2010. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics 7:275-282.
10. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R. 2008. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31:127-132.
11. D'Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP. 1997. Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76:367-376.
12. Down JL. 1887. On some of the mental affections of childhood and youth. London, UK: McKeith Press.
13. Dykens EM, Hodapp RM. 2007. Three steps toward improving the measurement of behavior in behavioral phenotype research. Child Adolesc Psychiatr Clin N Am 16:617-630.
14. Dykens EM, Hodapp RM, Ort S, Finucane B, Shapiro LR, Leckman JF. 1989. The trajectory of cognitive development in males with fragile X syndrome. J Am Acad Child Adolesc Psychiatry 28:422-426.
15. Dykens EM, Hodapp RM, Ort SI, Leckman JF. 1993. Trajectory of adaptive behavior in males with fragile X syndrome. J Autism Dev Disord 23:135-145.
16. Dykens EM, Goff BJ, Hodapp RM, Davis L, Devanzo P, Moss F, Halliday J, Shah B, State M, King B. 1997. Eating themselves to death: Have "personal rights" gone too far in treating people with Prader-Willi syndrome? Ment Retard 35:312-314.
17. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. 2008. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 14:843-848.
18. Ehninger D, de Vries PJ, Silva AJ. 2009. From mTOR to cognition: Molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res 53:838-851.
19. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Hardy K, Hankerson JG, Doudet DD, Cohen RM. 1996. Presynaptic dopaminergic deficits in Lesch-Nyhan Disease. N Engl J Med 334:1568-1604.
20. Ess KC. 2010. Tuberous sclerosis complex: A brave new world? Curr Opin Neurol 23:189-193.
21. Feinstein C, Singh S. 2007. Social phenotypes in neurogenetic syndromes. Child Adolesc Psychiatr Clin N Am 16:631-647.
22. Fisch GS, Simensen R, Tarleton J, Chalifoux M, Holden JJ, Carpenter N, Howard-Peebles PN, Maddalena A. 1996. Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: A prospective multicenter analysis. Am J Med Genet 64:356-361.
23. Fisch GS, Carpenter N, Holden JJ, Howard-Peebles PN, Maddalena A, Borghgraef M, Steyaert J, Fryns JP. 1999a. Longitudinal changes in cognitive and adaptive behavior in fragile X females: A prospective multicenter analysis. Am J Med Genet 83:308-312.
24. Fisch GS, Hao HK, Bakker C, Oostra BA. 1999b. Learning and memory in the FMR1 knockout mouse. Am J Med Genet 84:277-282.
25. Fisch GS, Carpenter N, Howard-Peebles PN, Holden JJ, Tarleton J, Simensen R. 2010. The course of cognitive-behavioral development in children with the FMR1 mutation, Williams-Beuren syndrome, and neurofibromatosis type 1: The effect of gender. Am J Med Genet Part A 152A:1498-1509.
26. Flint J. 1998. Behavioral phenotypes: Conceptual and methodological issues. Am J Med Genet 81:235-240.
27. Flint J, Yule W. 1994. Behavioural phenotypes. In: Rutter M, Taylor E, Hersov L, editors. Child and adolescent psychiatry, 3rd edition. Oxford, England: Blackwell Scientific. pp. 666-687.
28. Frangiskakis JM, Ewart A, Morris C, Mervis C, Bertrand J, Robinson B, Klei B, Ensing G, Everett L, Green ED, Pröschel C, Gutowski NJ, Noble M, Atkinson DL, Odelberg SJ, Keating MT. 1996. LIM-kinase 1 hemizygosity implicated in impaired visuospatial constructive cognition. Cell 86:59-69.
29. Gao MC, Bellugi U, Dai L, Mills DL, Sobel EM, Lange K, Korenberg JR. 2010. Intelligence in Williams syndrome is related to STX1A, which encodes a component of the presynaptic SNARE complex. PLoS ONE 5:e10292.
30. Gath A, Gumley D. 1986. Behavior problems in retarded children with special reference to Down's syndrome. Br J Psychiatr 149:156-161.
31. Gothelf D, Feinstein C, Thompson T, Gu E, Penniman L, Van Stone E, Kwon H, Eliez S, Reiss AL. 2007. Neuropsychiatric risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry 164:663-669.
32. Gray V, Karmiloff-Smith A, Funnell E, Tassabehji M. 2006. In-depth analysis of spatial cognition in Williams syndrome: A critical assessment of the role of the LIMK1 gene. Neuropsychologia 44:679-685.
33. Greenberg N, MacLean PD, Ferguson JL. 1979. Role of the paleostriatum in species-typical display behavior of the lizard (Anolis carolinensis). Brain Res 172:229-241.
34. Gunn P, Berry P, Andrews RJ. 1981. The temperament of Down's syndrome in infants: A research note. J Child Psychol Psychiatry 22:189-194.
35. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M. 2009. Advances in the treatment of fragile X syndrome. Pediatrics 123:378-390.
36. Hall SS. 2009. Treatments for fragile X syndrome: A closer look at the data. Dev Disabil Res Rev 15:353-360.
37. Harris JC. 1998. Behavioral phenotypes. In: Assessment, diagnosis and treatment of the developmental disorders. New York: Oxford University Press. pp. 251-374.
38. Harris JC. 2001. Behavioral phenotypes: Portals into the developing brain. In: Davis K, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The 5th generation of progress. Baltimore: Lippincott Williams & Wilkins. pp. 625-638.
39. Harris J. 2009. Lesch-Nyhan disease. La Jolla, CA: Neurobase, Arbor Publishing Corporation.
40. Harris JC. 2010. Autism spectrum diagnoses in neurogenetic syndromes: Phenocopies of autism? In: Hollander E, Kolevzon A, Coyle JT, editors. Textbook of autism spectrum disorders. Arlington, VA: APA Press.
41. Harris JC, Lee RR, Jinnah HA, Wong DF, Yaster M, Bryan RN. 1998. Craniocerebral magnetic resonance imaging measurement and findings in Lesch-Nyhan syndrome. Arch Neurol 55:547-553.
42. Harris JC, Wong DF, Jinnah HA, Schretlen D, Barker P. 2002. Neuroimaging studies in Lesch-Nyhan syndrome and Lesch-Nyhan variants. In: Schroeder S, Oster-Granite M, Thompson T, editors. Self-injurious behavior: Gene-brain-behavior relationships. Washington, DC: American Psychological Association. pp. 269-278.
43. Hooper M, Hardy K, Handyside A, Hunter S, Monk M. 1987. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germ line colonization by cultured cells. Nature 326:292-295.
44. Jin P, Warren ST. 2000. Understanding the molecular basis of fragile X syndrome. Hum Mol Genet 9:901-908.
45. Jinnah HA, Jones MD, Wojcik BE, Rothstein JD, Hess EJ, Friedmann T, Breese GR. 1999. Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 72:225-229.
46. Jinnah HA, Visser JE, Harris JC, Verdu A, Larovere L, Ceballos-Picot I, Gonzalez-Alegre P, Neychev V, Torres RJ, Dulac O, Desguerre I, Schretlen DJ, Robey KL, Barabas G, Bloem BR, Nyhan W, De Kremer R, Eddey GE, Puig JG, Reich SG. 2006. Lesch-Nyhan Disease International Study Group. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 129:1201-1217.
47. Kooy RF, D'Hooge R, Reyniers E. 1996. Transgenic mouse model for the fragile X syndrome. Am J Med Genet 64:241-245.
48. Kuehn MR, Bradley A, Robertson EJ, Evans MJ. 1987. A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326:295-298.
49. Lloyd KG, Hornykiewicz O, Davidson L, Shannak K, Farley I, Goldstein M, Shibuya M, Kelley WN, Fox IH. 1981. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 305:1106-1111.
50. MacLean PD. 1978. Effects of lesions of globus pallidus on species-typical display behavior of squirrel monkeys. Brain Res 149:175-196.
51. Meng Y, Zhang Y, Tregoubov V, Janus C, Cruz L, Jackson M, Lu WY, MacDonald JF, Wang JY, Falls DL, Jia Z. 2002. Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice. Neuron 35:121-133.
52. Merla G, Brunetti-Pierri N, Micale L, Fusco C. 2010. Copy number variants at Williams-Beuren syndrome 7q11.23 region. Hum Genet 28:3-26.
53. Moss J, Howlin P. 2009. Autism spectrum disorders in genetic syndromes: Implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. J Intellect Disabil Res 53:852-873.
54. Murphy K, Jones L, Owen M. 1999. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56:940-955.
55. Muzykewicz DA, Newberry P, Danforth N, Halpern EF, Thiele EA. 2007. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav 11:506-513.
56. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. 2007. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci USA 104:15537-15542.
57. Napolioni V, Moavero R, Curatolo P. 2009. Recent advances in neurobiology of tuberous sclerosis complex. Brain Dev 31:104-113.
58. Nyhan W. 1972. Behavioral phenotypes in organic genetic disease. Presidential address to the Society for Pediatric Research, May 1, 1971. Pediatr Res 6:1-9.
59. Nyhan W. 1976. Behavior in Lesch-Nyhan syndrome. J Autism Child Schizophr 6:235-252.
60. Page T, Bakay B, Nissinen E, Nyhan WL. 1981. Hypoxanthine-guanine phosphoribosyltransferase variants: Correlation of clinical phenotype with enzyme activity. J Inherit Metab Dis 4:203-206.
61. Pober BR. 2010. Williams-Beuren syndrome. N Engl J Med 362:239-252.
62. Pralong E, Pollo C, Coubes P, Bloch J, Roulet E, Tétreault MH, Debatisse D, Villemure JG. 2005. Electrophysiological characteristics of limbic and motor globus pallidus internus (GPI) neurons in two cases of Lesch-Nyhan syndrome. Neurophysiol Clin 35:168-173.
63. Pralong E, Pollo C, Villemure JG, Debatisse D. 2007. Opposite effects of internal globus pallidus stimulation on pallidal neurones activity. Mov Disord 22:1879-1884.
64. Rueda JR, Ballesteros J, Tejada MI. 2009. Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol 9:53.
65. Schretlen DJ, Harris JC, Park KS, Jinnah HA, del Pozo NO. 2001. Neurocognitive functioning in Lesch-Nyhan disease and partial hypoxanthine-guanine phosphoribosyltransferase deficiency. J Int Neuropsychol Soc 7:805-812.
66. Schretlen DJ, Ward J, Meyer SM, Yun J, Puig JG, Nyhan WL, Jinnah HA, Harris JC. 2005. Behavioral aspects of Lesch-Nyhan disease and its variants. Dev Med Child Neurol 47:673-677.
67. Steinhausen HC, Von Gontard A, Spohr HL, Hauffa BP, Eiholzer U, Backes M, Willms J, Malin Z. 2002. Behavioral phenotypes in four mental retardation syndromes: Fetal alcohol syndrome, Prader-Willi syndrome, fragile X syndrome, and tuberous sclerosis. Am J Med Genet 111:381-387.
68. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. 2010. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 107:11591-11596.
69. Swillen A, Devriendt K, Legius E. 1999. The behavioral phenotype in velo-cardio-facial syndrome (VCFS): From infancy to adolescence. Genet Couns 10:79-88.
70. Taira T, Kobayashi T, Hori T. 2003. Disappearance of self-mutilating behavior in a patient with Lesch-Nyhan syndrome after bilateral chronic stimulation of the globus pallidus internus. Case report. J Neurosurg 98:414-416.
71. Tassabehji M. 2003. Williams-Beuren syndrome: A challenge for genotype-phenotype correlations. Hum Mol Genet 12:R229-R237.
72. Tassabehji M, Metcalfe K, Karmiloff-Smith A, Carette MJ, Grant J, Dennis N, Reardon W, Splitt M, Read AP, Donnai D. 1999. Williams syndrome: Use of chromosomal microdeletions as a tool to dissect cognitive and physical phenotypes. Am J Hum Genet 64:118-125.
73. Visser JE, Smith DW, Moy SS, Breese GR, Friedmann T, Rothstein JD, Jinnah HA. 2002. Oxidative stress and dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. Brain Res Dev Brain Res 133:127-139.
74. Williamson DJ, Hooper ML, Melton DW. 1992. Mouse models of hypoxanthine phosphoribosyltransferase deficiency. J Inherit Metab Dis 15:665-673.
75. Wong DF, Harris JC, Naidu S, Yokoi F, Marenco S, Dannals RF, Ravert HT, Yaster M, Evans A, Rousset O, Bryan RN, Gjedde A, Kuhar MJ, Breese GR. 1996. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci USA 93:5539-55343.